

Alexander G. Mietheke,¹ Adib Moukarzel,² Gilda Porta,³ Joshue Covarrubias Esquer,⁴ Piotr Czubkowski,⁵ Felipe Ordóñez,⁶ Antonella Mosca,⁷ Amal A. Aqul,⁸ Robert H. Squires,⁹ Etienne Sokal,¹⁰ Daniel D'Agostino,¹¹ Ulrich Baumann,¹² Lorenzo D'Antiga,¹³ Nagraj Kasi,¹⁴ Nolwenn Laborde,¹⁵ Cigdem Arıkan,¹⁶ Chuan-Hao Lin,¹⁷ Susan Gilmour,¹⁸ Naveen Mittal,¹⁹ Fang Kuan Chiou,²⁰ Simon P. Horslen,⁹ Wolf-Dietrich Huber,²¹ Tiago Nunes,²² Anamaria Lascu,²² Lara Longpre,²² Douglas B. Mogul,²² Marshall Baek,²² Pamela Vig,²² Vera F. Hupertz,²³ Regino Gonzalez-Peralta,²⁴ Udemé Ekong,²⁵ Jane Hartley,²⁶ Noémie Laverdue,²⁷ Nadia Ovchinsky,²⁸ Richard J. Thompson²⁹

^bSubtypes nt-BSEP, FIC1, MDR3, TJP2, and MYO5B were included in the efficacy analyses.

1. Loomes KM, et al. *Hepatol Commun*. 2022;6:2379-2390. 2. LIVMARLI® (marilixibat) [prescribing information]. Foster City, CA: Mirum Pharmaceuticals Inc. Mar 2023 3. LIVMARLI® (marilixibat) [summary of product characteristics]. Amsterdam, Netherlands: Mirum Pharmaceuticals International B.V. Nov 2023. 4. ClinicalTrials.gov identifier: NCT03905303. Updated December 11, 2023. Accessed January 25, 2024. <https://www.clinicaltrials.gov/study/NCT03905303>. 5. Miettke A, et al. Oral presentation at NASPGHAN 2023. 6. ClinicalTrials.gov identifier: NCT04185363. Updated October 5, 2023. Accessed January 25, 2024. <https://www.clinicaltrials.gov/study/NCT04185363>. 7. Kamath BM, et al. *Hepatology*. 2020;4:1012-1018.